Core Viewpoint - 博拓生物 reported a significant decline in both revenue and net profit for the first half of 2025, primarily due to external factors such as tariffs and reduced demand for certain products [1] Financial Performance - The company achieved an operating revenue of 203 million yuan, representing a year-on-year decrease of 23.91% [1] - The net profit attributable to shareholders was 12.4 million yuan, down 82.82% year-on-year [1] - Basic earnings per share were reported at 0.07 yuan [1] Factors Affecting Performance - Revenue from the U.S. market decreased due to the impact of tariffs and a slowdown in government procurement [1] - Domestic demand for respiratory testing products declined due to cyclical fluctuations, while demand for dengue fever and other mosquito-borne products in Latin America also decreased [1] - Increased registration fees and share-based payment expenses from employee stock ownership plans contributed to the financial strain, alongside reduced foreign exchange gains and interest income [1]